Ignacio V. Matos
Madrid, MD, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 43 publications
Prognostic value of existing scoring systems for early mortality in phase I immunotherapy trials: a head-to-head real-world cohort study.
Journal: Frontiers in oncology
Published: April 07, 2026
Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer.
Journal: Cancer research communications
Published: March 10, 2026
Autocrine activity of engineered IL-33 mRNA enhances adoptive T-cell therapy for peritoneal carcinomatosis and synergizes with IL-12 mRNA.
Journal: Theranostics
Published: July 21, 2025
Fcγ receptors and immunomodulatory antibodies in cancer.
Journal: Nature reviews. Cancer
Published: October 10, 2023
Survival and safety after neoadjuvant chemotherapy or upfront surgery for locally advanced colon cancer: meta-analysis.
Journal: The British journal of surgery
Published: July 27, 2023
Druggable Targets in Cytokine Release Syndromes.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 26, 2023
Author Correction: Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling.
Journal: Nature cancer
Published: November 14, 2022
Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 24, 2022
Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials.
Journal: The oncologist
Published: August 08, 2022
Erratum to 'Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors': [ESMO Open Volume 7, Issue 2, April 2022, 100447].
Journal: ESMO open
Published: July 16, 2022
Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling.
Journal: Nature cancer
Published: October 11, 2021
Last Updated: 09/26/2026